capecitabine

Type: Keyphrase
Name: capecitabine
First reported Apr 23 2014 - Updated 14 hours ago - 6 reports

Revolutionary breast cancer drug "too expensive"

A new drug for breast cancer which extends women's lives by almost six months, and was trialled in the North East, is to be blocked from routine NHS access under draft guidance issued by a health watchdog.Kadcyla, manufactured by Roche, can cost more ... [Published itv.com - 17 hours ago]
First reported 19 hours ago - Updated 19 hours ago - 1 reports

Cost Control in the UK

Via the Guardian: A Herceptin-style drug that can offer some women with advanced breast cancer nearly six months of extra life has been turned down for use in the NHS because of its high cost. In draft guidance now open to consultation, the ... [Published Balloon Juice - 19 hours ago]
First reported Apr 22 2014 - Updated Apr 22 2014 - 1 reports

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit ...

Colorectal cancer (CRC) is a disease of the elderly. However, geriatric patients are often excluded from clinical trials.The combination of capecitabine, oxaliplatin and bevacizumab (XELOX/BEV) has not been assessed in an elderly population.Methods: We ... [Published 7thSpace - Apr 22 2014]
First reported Apr 18 2014 - Updated Apr 18 2014 - 1 reports

Forum Post: side effects after big op

> Cancer types> Bowel (colon & rectum) cancer> Bowel (Colon & Rectum) Cancer Group - Discussion Forum> side effects after big opDiscussion toolsKeywordsside effects after big opBowel (colon & rectum) cancerA group for anyone affected by colon, ... [Published Macmillan Cancer Support - Apr 18 2014]
Entities: Rectum, Cancer, capecitabine
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Maintenance Therapy for Colorectal Cancer

Maintenance therapy has become quite a hot topic for those of us working in the field of solid tumor malignancies. Our original concept of chemotherapy for solid tumors was to give a certain number of cycles and then stop treatment, or to continue treatment ... [Published Cancernetwork.com - Apr 17 2014]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

GI Research Improving Quality of Life in Rectal, Colorectal Cancers

Image ToolsImproving quality of life, through more convenient treatment for patients with rectal cancer and by reducing unnecessary treatment for patients with advanced colorectal cancer, was the subject of two studies presented at the Gastrointestinal ... [Published Oncology Times - Apr 16 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Trastuzumab emtansine: indication of major added benefit in 1 subpopulation

PUBLIC RELEASE DATE: 7-Apr-2014The antibody-drug conjugate trastuzumab emtansine (trade name: Kadcyla) has been approved since November 2013 for the treatment of patients with unresectable, locally advanced or metastatic breast cancer that is HER2-positive, ... [Published EurekAlert! - Apr 07 2014]
First reported Apr 07 2014 - Updated Apr 07 2014 - 1 reports

Again, Oxaliplatin Is Toxic and No Benefit in Rectal Cancer

VIENNA, Austria — Yet another rectal cancer study has found that the addition of oxaliplatin to capecitabine chemoradiation in locally advanced disease gives no short-term postoperative benefit and increases toxicity.The finding comes from new data from ... [Published American Journal of Public Health - Apr 07 2014]
First reported Apr 05 2014 - Updated Apr 05 2014 - 1 reports

Blog Post: Platelets

I went up to The Christie on Thursday for my 3-weekly review on Thurs (no Mytomycin this time).  My friend  from York met me at the station and we grabbed a nice lunch and a quick tour of the art gallery, as we usually do, before going to the hospital.  ... [Published Macmillan Cancer Support - Apr 05 2014]
First reported Apr 04 2014 - Updated Apr 04 2014 - 2 reports

Resected Pancreatic Cancer Why Wait for the Inevitable

Related Biotechnology, Pharmaceutical and Healthcare NewsDr. John Marshall reports on a retrospective study suggesting that maintenance with capecitabine is a promising option in patients with resected pancreatic adenocarcinoma after adjuvant therapy. ... [Published BioPortfolio - Apr 04 2014]
First reported Mar 31 2014 - Updated Apr 01 2014 - 3 reports

UPDATE 1-FDA allows Curis to resume testing cancer drug

March 31 (Reuters) - Curis Inc said the U.S. Food and Drug Administration allowed it to resume testing of its experimental cancer drug, lifting a November order halting enrolment in an early-stage trial.The drugmaker's shares rose as much as 13 percent ... [Published CNBC - Mar 31 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Drugs and Therapies: Researchers at Department of Clinical and Experimental Medicine Report New Data on Capecitabine Therapy

Today's Medical & Research NewsDrugs and Therapies2014 MAR 27 -- By a News Reporter-Staff News Editor at Clinical Trials Week -- Current study results on Drugs and Therapies have been published. According to news reporting out of Linkoping, Sweden, by ... [Published NewsRX - Mar 27 2014]

Quotes

...The general manager of Roche Products in the UK, Jayson Dallas, said the company is "extremely disappointed that NICE has failed to safeguard the interests of patients with this advanced stage of aggressive disease"
"Not only this, Kadcyla is also much better tolerated by women than current standard treatment options, causing much less in the way of traditional chemotherapy associated side effects."
Breakthrough Breast Cancer’s senior policy manager, Dr Caitlin Palframan, says in a statement: "The drug appraisal process in England, and the cost of drugs, must change if prospects for patients are going to improve. This is the third highly effective breast cancercancer drug to be rejected by NICE on the basis of cost in the last year and we will be responding to this latest decision, as well as the wider proposed changes to NICE’s drug appraisal process, in due course."

More Content

All (86) | News (81) | Reports (0) | Blogs (4) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
NICE rejects Roche's Kadcyla as "unaffordable" [Published PMLive - 1 hour ago]
Revolutionary breast cancer drug "too expensive" [Published itv.com - 17 hours ago]
Cost Control in the UK [Published Balloon Juice - 19 hours ago]
Breast cancer drug 'too costly' [Published BootsWebMD - 21 hours ago]
Breast cancer drug too dear for NHS [Published Pharma Field - 23 hours ago]
AbbVie to Present Data on Investigational Compo... [Published TickerTech.com - Apr 23 2014]
NICE set to block use of 'unaffordable' new bre... [Published Nursing Times - Apr 23 2014]
UK’s NICE rejects use of Roche’s Kadcyla for br... [Published Pharma Letter - Apr 23 2014]
New breast cancer drug ‘unaffordable’ for NHS [Published OnMedicanet - Apr 23 2014]
NICE rejects ‘costly’ cancer treatment for NHS use [Published National Health Executive - Apr 23 2014]
Watchdog blocks breast cancer drug [Published Croydon Guardian - Apr 23 2014]
Breast cancer drug turned down for NHS use due ... [Published Guardian.co.uk - Apr 23 2014]
Capecitabine in combination with oxaliplatin an... [Published 7thSpace - Apr 22 2014]
Nektar Presents Pipeline Data - Analyst Blog [Published Mr Top Step - Apr 19 2014]
Forum Post: side effects after big op [Published Macmillan Cancer Support - Apr 18 2014]
Maintenance Therapy for Colorectal Cancer [Published Cancernetwork.com - Apr 17 2014]
INCYTE - JAKAFI’s Label Expansion in Ref. Met... [Published PR inside - Apr 17 2014]
INCYTE - JAKAFI’s Label Expansion in Ref. Met... [Published Live-PR.com - Apr 17 2014]
GI Research Improving Quality of Life in Rectal... [Published Oncology Times - Apr 16 2014]
Sales of cancer drugs soar once again at Roche [Published Pharma Times - Apr 16 2014]
Roche may face EU levies following drug safety ... [Published Pharmafocus - Apr 15 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
ONLINE FIRST: 5-FU Overdose May Be Countered by... [Published Oncology Times - Apr 14 2014]
New Findings on Breast Cancer Described by Inve... [Published NewsRX - Apr 11 2014]
Nektar Presents Pipeline Data [Published Zacks.com - Apr 10 2014]
Forum Post: Starting chemo tomorrow [Published Macmillan Cancer Support - Apr 10 2014]
Cerulean Limps into Nasdaq Debut With $7 Per Sh... [Published Xconomy - Apr 10 2014]
Stepping up fight for cancer drug access [Published Wrexham Leader - Apr 09 2014]
Tumor-initiating cells and methods of use [Published PharmCast - Apr 09 2014]
Forum Post: Re: Chemotherapy and eyesight/joint... [Published Macmillan Cancer Support - Apr 07 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Cost Control in the UK [Published Balloon Juice - 19 hours ago]
Via the Guardian: A Herceptin-style drug that can offer some women with advanced breast cancer nearly six months of extra life has been turned down for use in the NHS because of its high cost. In draft guidance now open to consultation, the ...
CAPECITABINE Tablet, Film Coated [Teva Pharmace... [Published DailyMed Drug Label Updates for the last seven ... - Mar 07 2014]
Updated Date: Mar 7, 2014 EST ...
Teva Announces Launch of Generic Xeloda® Tablet... [Published Business Wire Health News - Mar 07 2014]
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Xeloda® (Capecitabine) Tablets, 150 MG and 500 MG, in the United States. Xeloda® is marketed by Genentech in the United States. ...
Oncothyreon and Array BioPharma Announce Initia... [Published PR Newswire: Health - Feb 03 2014]
SEATTLE AND BOULDER, CO, Feb. 3, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ:ONTY) and Array BioPharma Inc. (NASDAQ: ARRY) today announced theinitiation of a Phase 1b trial of ONT-380 (ARRY-380) in combinationwith Xeloda® (capecitabine) and/or Herceptin® ...
1

Press Releases

sort by: Date | Relevance
Scientific guideline: Draft capecitabine produc... [Published EMA Ongoing public consultations - Nov 15 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.